TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3100580

Group type: EXPERIMENTAL
Intervention: No explanation condition (minimal instructions on expected outcome)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Explanation condition (all possible sensations described and attributed to the effects of the gas)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Social phobics (both no explanation and explanation conditions)
Number of subjects: 32
Study: 31959397

Group type: EXPERIMENTAL
Intervention: Implant-supported cantilever fixed partial dentures (ICFPDs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Implant-supported conventional fixed partial dentures (IFF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both groups (ICFPDs and IFF)
Number of subjects: 14
Study: 27492975

Group type: EXPERIMENTAL
Intervention: Orafti® Inulin (3 x 4g daily for 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 44
Study: 26346980

Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 560
Study: 24260122

Group type: EXPERIMENTAL
Intervention: Dairy drink containing Lactobacillus casei Shirota
Number of subjects: 60

Group type: COMPARATOR
Intervention: Similar drink without bacteria (placebo)
Number of subjects: 60
Study: 21450187

Group type: EXPERIMENTAL
Intervention: Res-Care Intervention
Number of subjects: 487

Group type: COMPARATOR
Intervention: Control
Number of subjects: 487
Study: 19010561

Group type: EXPERIMENTAL
Intervention: Surgical clips for position verification
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NAL protocol based on surgical clips
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: eNAL protocol based on surgical clips
Number of subjects: 30
Study: 17674599

Group type: EXPERIMENTAL
Intervention: Urinary catheter removal at 10:00 p.m. (Group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Urinary catheter removal at 7:00 a.m. (Group B)
Number of subjects: 45
Study: 14692922

Group type: EXPERIMENTAL
Intervention: 10% sodium hydroxide applied for 2 minutes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% sodium hydroxide applied for 1 minute combined with curettage
Number of subjects: 60
Study: 11566619

Group type: EXPERIMENTAL
Intervention: Onercept 50 mg IV
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Onercept 150 mg IV
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Onercept 50 mg SC (single injection)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Onercept 50 mg SC (six repeated injections)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Onercept (various doses)
Number of subjects: 3
Study: 9470156

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVGG) at a dosage of 0.5 g/kg (range 0.25 to 0.73 g/kg) administered after 10.4 +/- 6.6 days of prednisone therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Prednisone therapy
Number of subjects: 13
Study: 7801748

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retrospective studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random check of articles
Number of subjects: 0
Study: 3616553

Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 3 Hz
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Whole-body vibration at 6 Hz
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control situation (sitting for 1 h without vibration)
Number of subjects: 15
Study: 30204730

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment guided by visual acuity stabilization criteria (Group I)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment guided by disease activity (Group II)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Verteporfin photodynamic therapy (Group III)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Ranibizumab injections (Groups I/II)
Number of subjects: 457
Study: 28010989

Group type: COMPARATOR
Intervention: Standard repair alone
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Mesh augmentation
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Graft augmentation
Number of subjects: 1352
Study: 25517761

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) with 3 × 5 min occlusion at 220 mmHg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) with 3 × 5 min occlusion at 50 mmHg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo treatment with 3 × 5 min occlusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) in female cohort
Number of subjects: 16
Study: 23668624

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/day)
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI)
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Naltrexone + CBI
Number of subjects: 863

Group type: COMPARATOR
Intervention: Placebo Naltrexone
Number of subjects: 863
Study: 21192150

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Citalopram or Fluoxetine (dose increase at week 6)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: SSRI plus cognitive behavior therapy
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Venlafaxine plus cognitive behavior therapy
Number of subjects: 334
Study: 19167721

Group type: EXPERIMENTAL
Intervention: Automated external defibrillators (AEDs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual defibrillators (MDs)
Number of subjects: 60
Study: 17123235

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg (GRA1) + 8 mg dexamethasone
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg (GRA3) + 8 mg dexamethasone
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg (OND8) + 8 mg dexamethasone
Number of subjects: 738
Study: 15128726

Group type: EXPERIMENTAL
Intervention: Intervention group (received a three-item questionnaire)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Intervention group (compared with a similar group of 151 patients observed during a 2 month period preceding the study)
Number of subjects: 251
Study: 11486981

Group type: EXPERIMENTAL
Intervention: Therapeutic outcomes monitoring (TOM)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (no TOM)
Number of subjects: 350
Study: 9482177

Group type: EXPERIMENTAL
Intervention: Ebselen (150 mg, twice a day for 2 weeks)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Ebselen
Number of subjects: 286
Study: 8059693

Group type: COMPARATOR
Intervention: Volume loading (mean 400 ml saline solution)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dobutamine (5 micrograms/kg/min)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dobutamine (10 micrograms/kg/min)
Number of subjects: 11
Study: 3143264

Group type: EXPERIMENTAL
Intervention: Insulin and glyburide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin plus placebo
Number of subjects: 20
Study: 31999774

Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging (DWI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water-Only plus Contrast (WOC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fat-Only (FO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fat-Only plus Contrast (FOC)
Number of subjects: 30
Study: 29035128

Group type: EXPERIMENTAL
Intervention: Plasma homocysteine levels (highest vs lowest quartile)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Total folate intake (quartiles)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Vitamin B6 intake from food (quartiles)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Betaine intake (quartiles)
Number of subjects: 292
Study: 29121326

Group type: EXPERIMENTAL
Intervention: Increased FSH dose (225/450 IU/day)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Standard FSH dose (150 IU/day)
Number of subjects: 511
Study: 26694150

Group type: COMPARATOR
Intervention: 80kV/300mAs (Group 1; n. 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 80kV/400mAs (Group 2; n. 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 80kV/500mAs (Group 3; n. 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 120kV (all patients)
Number of subjects: 60
Study: 23669884

Group type: EXPERIMENTAL
Intervention: Internet-delivered interpersonal psychotherapy (IPT)
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (CBT)
Number of subjects: 1843

Group type: COMPARATOR
Intervention: Active control treatment (MoodGYM)
Number of subjects: 1843
Study: 21878788

Group type: EXPERIMENTAL
Intervention: Short-term dynamic therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 50
Study: 19198042

Group type: EXPERIMENTAL
Intervention: Uncircumcised males during unprotected sexual contact
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of HSV-2 in either partner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of HIV in either partner
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 0
Study: 16858633

Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 33
Study: 15273918

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy in hypogonadal patients
Number of subjects: 88

Group type: COMPARATOR
Intervention: Basic therapy of calcium and vitamin D
Number of subjects: 88
Study: 11500195

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 189
Study: 9288515

Group type: EXPERIMENTAL
Intervention: Intermittent aortic cross clamping with fibrillation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Antegrade cold crystalloid cardioplegia
Number of subjects: 24
Study: 1774656

Group type: EXPERIMENTAL
Intervention: 2% hydroxypropyl methylcellulose (Occucoat)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Sodium hyaluronate (Healon)
Number of subjects: 222
Study: 6752712

Group type: EXPERIMENTAL
Intervention: Oxprenolol (40 mg twice daily)
Number of subjects: 1103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1103
Study: 30864259

Group type: EXPERIMENTAL
Intervention: EpiFix (dehydrated human amnion/chorion membrane allograft)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard care (moist dressings and multi-layer compression)
Number of subjects: 128
Study: 29089066

Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™) at a dose of 20 mg/kg, administered orally 30 minutes after feeding.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Untreated control group (Groups 5 to 8).
Number of subjects: 64
Study: 26800687

Group type: EXPERIMENTAL
Intervention: 5-year exercise program with 200 min of physical activity (PA) per week
Number of subjects: 743

Group type: COMPARATOR
Intervention: Control group with 60 min of physical activity (PA) per week
Number of subjects: 743
Study: 23588935

Group type: EXPERIMENTAL
Intervention: HPV16 L1
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: HPV18 L1
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: HPV31 L1
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: HPV18
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: HPV52 and HPV58
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: Sexual exposure
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: Current or former smokers
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: Multiplex assay
Number of subjects: 2464
Study: 21835280

Group type: EXPERIMENTAL
Intervention: 600 mg dalcetrapib daily for 24 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo daily for 24 months
Number of subjects: 130
Study: 19252920

Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealing (BVS; BiClamp)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Conventional suture ligation
Number of subjects: 175
Study: 16703780

Group type: EXPERIMENTAL
Intervention: 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products only
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products along with oral doxycycline
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products along with oral minocycline
Number of subjects: 1089
Study: 14654718

Group type: EXPERIMENTAL
Intervention: GH 0.23 mg/kg/week (group A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GH 0.46 mg/kg/week (group B)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GH therapy (both groups)
Number of subjects: 26
Study: 11575685

Group type: EXPERIMENTAL
Intervention: Web survey group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mail survey group
Number of subjects: 0
Study: 9671870

Group type: EXPERIMENTAL
Intervention: Levofloxacin 250 mg once daily
Number of subjects: 186

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 186

Group type: COMPARATOR
Intervention: Lomefloxacin 400 mg once daily
Number of subjects: 186
Study: 7836549

Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex, THA) administered after an 8-hour overnight fast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex, THA) administered 1 hour before a standard breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex, THA) administered 15 minutes after beginning a standard breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex, THA) administered 2 hours after completion of a standard breakfast
Number of subjects: 0
Study: 3046277

Group type: EXPERIMENTAL
Intervention: Sotalol, 160 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atenolol, 50 mg twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous sotalol, 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous atenolol, 10 mg
Number of subjects: 10
Study: 30232383

Group type: EXPERIMENTAL
Intervention: Deep hypothermia
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: miR‐194‐5p mimic
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: miR‐194‐5p
Number of subjects: 21
Study: 26881447

Group type: EXPERIMENTAL
Intervention: Escitalopram + CBT (16 sessions)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Escitalopram (without CBT)
Number of subjects: 42
Study: 25919121

Group type: EXPERIMENTAL
Intervention: Atomoxetine in extensive/ultrarapid metabolizers
Number of subjects: 1936

Group type: EXPERIMENTAL
Intervention: Atomoxetine in intermediate metabolizers
Number of subjects: 1936

Group type: EXPERIMENTAL
Intervention: Atomoxetine in poor metabolizers
Number of subjects: 1936
Study: 23650294

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% gel
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 21068676

Group type: EXPERIMENTAL
Intervention: Creatine (PEG-creatine, 5 g·d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (maltodextrin powder, 5 g·d)
Number of subjects: 22
Study: 18222192

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 184

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 184
Study: 16360926

Group type: EXPERIMENTAL
Intervention: TJ‐15 (TSUMURA Orengedokuto Extract Granules)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 12675866

Group type: EXPERIMENTAL
Intervention: Dual blockade of the renin-angiotensin system (RAS) with irbesartan 300 mg (once daily) and enalapril 40 mg (once daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dual blockade of the renin-angiotensin system (RAS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: ACE inhibitors + placebo
Number of subjects: 24
Study: 10963287

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) plus medical treatment
Number of subjects: 962

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 962
Study: 9151611

Group type: EXPERIMENTAL
Intervention: One-stage IMZ implant placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-stage IMZ implant placement
Number of subjects: 0
Study: 8403954

Group type: EXPERIMENTAL
Intervention: Topical antibiotics (tobramycin, polymyxin E, amphotericin B, vancomycin)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo (suspension of fluid and paste without antibiotics)
Number of subjects: 123
Study: 2885854

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg per day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Terfenadine (120 mg per day)
Number of subjects: 42
Study: 29193563

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8213

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8213

Group type: EXPERIMENTAL
Intervention: SUA quintiles (Q5 vs. Q1)
Number of subjects: 8213
Study: 26841278

Group type: EXPERIMENTAL
Intervention: Empathy-feedback VP
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Backstory VP
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control VP
Number of subjects: 70
Study: 25020061

Group type: EXPERIMENTAL
Intervention: Fasting (72 hours)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (Postabsorptive state)
Number of subjects: 8
Study: 22941116

Group type: EXPERIMENTAL
Intervention: Somatic symptom burden reduction
Number of subjects: 405
Study: 20864555

Group type: EXPERIMENTAL
Intervention: High-polyphenol diet (PSPL group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-polyphenol diet (control group)
Number of subjects: 15
Study: 18211927

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Deep Sclerectomy with Collagen Implant (DSCI)
Number of subjects: 60
Study: 16357838

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: ASCT
Number of subjects: 349
Study: 14615655

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 2947
Study: 11106136

Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Paroxetine (20-40 mg)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Early response (25% reduction in MADRS scores at week 2)
Number of subjects: 353
Study: 8626359

Group type: EXPERIMENTAL
Intervention: Nefazodone (mean dose at endpoint = 379 mg/day)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 247
Study: 1336527

Group type: EXPERIMENTAL
Intervention: Captopril at 25 mg twice a day
Number of subjects: 265

Group type: COMPARATOR
Intervention: Atenolol at 50 mg once a day
Number of subjects: 265
Study: 6518669

Group type: EXPERIMENTAL
Intervention: Moderate dietary salt restriction
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 28
Study: 30972581

Group type: EXPERIMENTAL
Intervention: Fluoxetine or group cognitive-behavioral therapy for 14 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 29
Study: 29314872

Group type: EXPERIMENTAL
Intervention: Self-adherent tape
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lace-up ankle brace
Number of subjects: 29
Study: 26815709

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24361082

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 24
Study: 21702044

Group type: EXPERIMENTAL
Intervention: Catumaxomab
Number of subjects: 258
Study: 20551371

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331
Study: 18698012

Group type: EXPERIMENTAL
Intervention: Oral aspirin (162 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Topical methyl salicylate (5 g of 30% preparation)
Number of subjects: 9
Study: 16385104

Group type: EXPERIMENTAL
Intervention: Acute treatment strategies for migraine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive treatment strategies for migraine
Number of subjects: 0
Study: 12450883

Group type: EXPERIMENTAL
Intervention: High-protein, high-methionine diet (HP: 22% of total energy, 2.7 g methionine/d; n = 25)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low-protein, low-methionine diet (LP: 12% of total energy, 1.4 g methionine/d; n = 25)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control diet (intermediate protein content; n = 15)
Number of subjects: 65
Study: 10369491

Group type: EXPERIMENTAL
Intervention: Iron (14 mg/d) and 60 mg/d vitamin C (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iron (14 mg/d) and 260 mg/d vitamin C (Group B)
Number of subjects: 40
Study: 7575897

Group type: EXPERIMENTAL
Intervention: Infusions of 250 ml 10% HES 200/0.5
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Infusions of 500 ml 10% HES 200/0.5
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline infusions (previous study)
Number of subjects: 200
Study: 2190502

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl infusion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Epidural fentanyl infusion
Number of subjects: 28
Study: 786694

Group type: EXPERIMENTAL
Intervention: Salmefamol 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salmefamol 2 mg
Number of subjects: 12
Study: 30511426

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-exercise (sedentary) group
Number of subjects: 38
Study: 28068987

Group type: EXPERIMENTAL
Intervention: Acetyl-DL-leucine (up to 5 g per day)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Acetyl-DL-leucine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108